+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Nektar Therapeutics - Product Pipeline Review - 2015

  • ID: 3338409
  • Company Profile
  • June 2015
  • 70 pages
  • Global Markets Direct
1 of 4
Nektar Therapeutics - Product Pipeline Review - 2015

Summary

This, ‘Nektar Therapeutics - Product Pipeline Review - 2015’, provides an overview of the Nektar Therapeutics’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Nektar Therapeutics’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Nektar Therapeutics including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Nektar Therapeutics’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Nektar Therapeutics’s pipeline products

Reasons to buy

- Evaluate Nektar Therapeutics’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Nektar Therapeutics in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Nektar Therapeutics’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Nektar Therapeutics and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nektar Therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Nektar Therapeutics and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4

Loading
LOADING...

3 of 4
List of Tables
List of Figures
Nektar Therapeutics Snapshot
Nektar Therapeutics Overview
Key Information
Key Facts
Nektar Therapeutics - Research and Development Overview
Key Therapeutic Areas
Nektar Therapeutics - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Nektar Therapeutics - Pipeline Products Glance
Nektar Therapeutics - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Nektar Therapeutics - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Nektar Therapeutics - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Nektar Therapeutics - Drug Profiles
etirinotecan pegol
Product Description
Mechanism of Action
R&D Progress
NKTR-181
Product Description
Mechanism of Action
R&D Progress
NKTR-171
Product Description
Mechanism of Action
R&D Progress
NKTR-125
Product Description
Mechanism of Action
R&D Progress
NKTR-140
Product Description
Mechanism of Action
R&D Progress
NKTR-173
Product Description
Mechanism of Action
R&D Progress
NKTR-174
Product Description
Mechanism of Action
R&D Progress
NKTR-192
Product Description
Mechanism of Action
R&D Progress
NKTR-194
Product Description
Mechanism of Action
R&D Progress
NKTR-195
Product Description
Mechanism of Action
R&D Progress
NKTR-196
Product Description
Mechanism of Action
R&D Progress
NKTR-214
Product Description
Mechanism of Action
R&D Progress
NKTR-218
Product Description
Mechanism of Action
R&D Progress
NKTR-223
Product Description
Mechanism of Action
R&D Progress
NKTR-228
Product Description
Mechanism of Action
R&D Progress
NKTR-230
Product Description
Mechanism of Action
R&D Progress
NKTR-255
Product Description
Mechanism of Action
R&D Progress
Proteins for Hematological Disorders
Product Description
Mechanism of Action
R&D Progress
Drug to Inhibit Kinase for Cancer
Product Description
Mechanism of Action
R&D Progress
Protein for Oncology
Product Description
Mechanism of Action
R&D Progress
Protein to Agonize Cytokine Receptor for Inflammation
Product Description
Mechanism of Action
R&D Progress
Protein to Agonize Cytokine Receptor for Viral Infections
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize NMDA Receptor for Pain and Depression
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Folate for Oncology
Product Description
Mechanism of Action
R&D Progress
Nektar Therapeutics - Pipeline Analysis
Nektar Therapeutics - Pipeline Products by Target
Nektar Therapeutics - Pipeline Products by Route of Administration
Nektar Therapeutics - Pipeline Products by Molecule Type
Nektar Therapeutics - Pipeline Products by Mechanism of Action
Nektar Therapeutics - Recent Pipeline Updates
Nektar Therapeutics - Dormant Projects
Nektar Therapeutics - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
NKTR-105
NKTR-192
Nektar Therapeutics - Company Statement
Nektar Therapeutics - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Nektar Therapeutics, Key Information
Nektar Therapeutics, Key Facts
Nektar Therapeutics - Pipeline by Indication, 2015
Nektar Therapeutics - Pipeline by Stage of Development, 2015
Nektar Therapeutics - Monotherapy Products in Pipeline, 2015
Nektar Therapeutics - Partnered Products in Pipeline, 2015
Nektar Therapeutics - Partnered Products/ Combination Treatment Modalities, 2015
Nektar Therapeutics - Out-Licensed Products in Pipeline, 2015
Nektar Therapeutics - Out-Licensed Products/ Combination Treatment Modalities, 2015
Nektar Therapeutics - Phase III, 2015
Nektar Therapeutics - Phase II, 2015
Nektar Therapeutics - Phase I, 2015
Nektar Therapeutics - Preclinical, 2015
Nektar Therapeutics - Discovery, 2015
Nektar Therapeutics - Pipeline by Target, 2015
Nektar Therapeutics - Pipeline by Route of Administration, 2015
Nektar Therapeutics - Pipeline by Molecule Type, 2015
Nektar Therapeutics - Pipeline Products by Mechanism of Action, 2015
Nektar Therapeutics - Recent Pipeline Updates, 2015
Nektar Therapeutics - Dormant Developmental Projects,2015
Nektar Therapeutics - Discontinued Pipeline Products, 2015
Nektar Therapeutics, Other Locations
Nektar Therapeutics, Subsidiaries

List of Figures
Nektar Therapeutics - Pipeline by Top 10 Indication, 2015
Nektar Therapeutics - Pipeline by Stage of Development, 2015
Nektar Therapeutics - Monotherapy Products in Pipeline, 2015
Nektar Therapeutics - Partnered Products in Pipeline, 2015
Nektar Therapeutics - Out-Licensed Products in Pipeline, 2015
Nektar Therapeutics - Pipeline by Top 10 Target, 2015
Nektar Therapeutics - Pipeline by Top 10 Route of Administration, 2015
Nektar Therapeutics - Pipeline by Top 10 Molecule Type, 2015
Nektar Therapeutics - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll